National Academies Press: OpenBook

Closing Evidence Gaps in Clinical Prevention (2022)

Chapter:Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force

« Previous: 5 Recommendations
Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×

A

Topics with “I Statements” from the U.S. Preventive Services Task Force

This appendix contains a summary table (see Table A-1) of all topics addressed by the U.S. Preventive Services Task Force (USPSTF) that include an “I statement” for at least one recommendation regarding the topic. Some topics have only one grade (e.g., screening for hearing loss in older adults), while some have multiple “I statements” along with letter grade recommendations for different aspects of a preventive service (e.g., screening for breast cancer), and still others have a letter grade for one group and an “I statement” for another group (e.g., screening for unhealthy drug use).

Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×

TABLE A-1 Topics with “I Statements” from the U.S. Preventive Services Task Force

Topic Name Year Grade Specific Recommendation
Chlamydia and Gonorrhea: Screening1 2021 B The USPSTF recommends screening for chlamydia in sexually active women age 24 years and younger and in older women who are at increased risk for infection.
B The USPSTF recommends screening for gonorrhea in sexually active women age 24 years and younger and in older women who are at increased risk for infection.
I The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men.
Gestational Diabetes: Screening2 2021 B Asymptomatic pregnant persons at 24 weeks of gestation or after
I Asymptomatic pregnant persons before 24 weeks of gestation
Vitamin D Deficiency in Adults: Screening3 2021 I
Hearing Loss in Older Adults: Screening4 2021 I

________________________

1USPSTF, 2021a.

2USPSTF, 2021b.

3USPSTF, 2021e.

4USPSTF, 2021c.

Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions5 2021 A The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and U.S. Food and Drug Administration (FDA)-approved pharmacotherapy for cessation to nonpregnant adults who use tobacco.
A The USPSTF recommends that clinicians ask all pregnant persons about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation to pregnant persons who use tobacco.
I The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of pharmacotherapy interventions for tobacco cessation in pregnant persons.
I The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of electronic cigarettes (e-cigarettes) for tobacco cessation in adults, including pregnant persons. The USPSTF recommends that clinicians direct patients who use tobacco to other tobacco cessation interventions with proven effectiveness and established safety. See the Practice Considerations section for more information on recommended behavioral interventions and pharmacotherapy and for suggestions for practice regarding the I statements.
High Blood Pressure in Children and Adolescents: Screening6 2020 I
Unhealthy Drug Use: Screening7 2020 B Adults aged 18 and older
I Adolescents
Illicit Drug Use in Children, Adolescents, and Young Adults: Primary Care–Based Interventions8 2020 I

________________________

5USPSTF, 2021d.

6USPSTF, 2020c.

7USPSTF, 2020f.

8USPSTF, 2020d.

Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Tobacco Use in Children and Adolescents: Primary Care Interventions9 2020 B School-aged children and adolescents who have not started to use tobacco
I School-aged children and adolescents who use tobacco
Bacterial Vaginosis in Pregnant Persons to Prevent Preterm Delivery: Screening10 2020 D Pregnant persons not at increased risk for preterm delivery
I Pregnant persons at increased risk for preterm delivery
Cognitive Impairment in Older Adults: Screening11 2020 I
Abdominal Aortic Aneurysm: Screening12 2019 B The USPSTF recommends 1-time screening for abdominal aortic aneurysm (AAA) with ultrasonography in men aged 65 to 75 years who have ever smoked.
C The USPSTF recommends that clinicians selectively offer screening for AAA with ultrasonography in men aged 65–75 years who have never smoked rather than routinely screening all men in this group. Evidence indicates that the net benefit of screening all men in this group is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms on the basis of evidence relevant to the patient’s medical history, family history, other risk factors, and personal values.
D The USPSTF recommends against routine screening for AAA with ultrasonography in women who have never smoked and have no family history of AAA.
I The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for AAA with ultrasonography in women aged 65–75 years who have ever smoked or have a family history of AAA.

________________________

9USPSTF, 2020e.

10USPSTF, 2020a.

11USPSTF, 2020b.

12USPSTF, 2019a.

Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Elevated Blood Lead Levels in Children and Pregnant Women: Screening13 2019 I The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for elevated blood lead levels in asymptomatic pregnant persons.
I The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for elevated blood lead levels in asymptomatic children.
Child Maltreatment: Interventions14 2018 I
Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions15 2018 B Adults 18 years or older, including pregnant women
I Adolescents aged 12–17 years
Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: Screening16 2018 B Women of reproductive age
I Older or vulnerable adults
Atrial Fibrillation: Screening with Electrocardiography17 2018 I
Peripheral Artery Disease and Cardiovascular Disease: Screening and Risk Assessment with the Ankle-Brachial Index18 2018 I
Cardiovascular Disease: Risk Assessment with Nontraditional Risk Factors19 2018 I

________________________

13USPSTF, 2019b.

14USPSTF, 2018e.

15USPSTF, 2018j.

16USPSTF, 2018f.

17USPSTF, 2018b.

18USPSTF, 2018h.

19USPSTF, 2018d.

Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Osteoporosis to Prevent Fractures: Screening20 2018 B Women 65 years and older
B Postmenopausal women younger than 65 years at increased risk of osteoporosis
I Men
Cardiovascular Disease Risk: Screening with Electrocardiography21 2018 D Adults at low risk of cardiovascular disease (CVD) events
I Adults at intermediate or high risk of CVD events
Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication22 2018 D The USPSTF recommends against daily supplementation with 400 IU or less of vitamin D and 1,000 mg or less of calcium for the primary prevention of fractures in community-dwelling, postmenopausal women.
I The USPSTF concludes that the current evidence is insufficient to assess the balance of the benefits and harms of vitamin D and calcium supplementation, alone or combined, for the primary prevention of fractures in men and premenopausal women.
I The USPSTF concludes that the current evidence is insufficient to assess the balance of the benefits and harms of daily supplementation with doses greater than 400 IU of vitamin D and greater than 1000 mg of calcium for the primary prevention of fractures in community-dwelling, postmenopausal women.
Skin Cancer Prevention: Behavioral Counseling23 2018 B Young adults, adolescents, children, and parents of young children
C Adults older than 24 years with fair skin types
I Adults
Adolescent Idiopathic Scoliosis: Screening24 2018 I

________________________

20USPSTF, 2018g.

21USPSTF, 2018c.

22USPSTF, 2018k.

23USPSTF, 2018i.

24USPSTF, 2018a.

Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Vision in Children Ages 6 Months to 5 Years: Screening25 2017 B Children aged 3–5 years
I Children younger than 3 years
Celiac Disease: Screening26 2017 I
Gynecological Conditions: Periodic Screening with the Pelvic Examination27 2017 I
Obstructive Sleep Apnea in Adults: Screening28 2017 I
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication29 2016 B Adults aged 40 to 75 years with no history of CVD, 1 or more CVD risk factors, and a calculated 10-year CVD event risk of 10% or greater
C Adults aged 40 to 75 years with no history of CVD, 1 or more CVD risk factors, and a calculated 10-year CVD event risk of 7.5% to 10%
I Adults 76 years and older with no history of CVD
Lipid Disorders in Children and Adolescents: Screening30 2016 I
Skin Cancer: Screening31 2016 I
Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication32 2016 B Adults aged 50–59 years with a 10% or greater 10-year CVD risk
C Adults aged 60–69 years with a 10% or greater 10-year CVD risk
I Adults younger than 50 years
I Adults aged 70 or older

________________________

25USPSTF, 2017d.

26USPSTF, 2017a.

27USPSTF, 2017b.

28USPSTF, 2017c.

29USPSTF, 2016h.

30USPSTF, 2016f.

31USPSTF, 2016g.

32USPSTF, 2016a.

Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Impaired Visual Acuity in Older Adults: Screening33 2016 I
Autism Spectrum Disorder in Young Children: Screening34 2016 I
Depression in Children and Adolescents: Screening35 2016 B Adolescents aged 12–18 years
2016 I Children aged 11 years or younger
Breast Cancer: Screening36 2016 B Women aged 50–74 years
C Women aged 40–49 years
I All women
I Women with dense breasts
I Women aged 75 years or older
Iron Deficiency Anemia in Young Children: Screening37 2015 I
Iron Deficiency Anemia in Pregnant Women: Screening and Supplementation38 2015 I
Speech and Language Delay and Disorders in Children Age 5 and Younger: Screening39 2015 I
Thyroid Dysfunction: Screening40 2015 I
Suicide Risk in Adolescents, Adults, and Older Adults: Screening41 2014 I

________________________

33USPSTF, 2016e.

34USPSTF, 2016b.

35USPSTF, 2016d.

36USPSTF, 2016c.

37USPSTF, 2015b.

38USPSTF, 2015a.

39USPSTF, 2015c.

40USPSTF, 2015d.

41USPSTF, 2014b.

Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Dental Caries in Children from Birth Through Age 5 Years: Screening42 2014 B Children from Birth Through Age 5 Years: The USPSTF recommends that primary care clinicians prescribe oral fluoride supplementation starting at age 6 months for children whose water supply is deficient in fluoride.
B Children from Birth Through Age 5 Years: The USPSTF recommends that primary care clinicians apply fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption.
I Children from Birth Through Age 5 Years: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of routine screening examinations for dental caries performed by primary care clinicians in children from birth to age 5 years.
Vitamin Supplementation to Prevent Cancer and CVD: Preventive Medication43 2014 D The USPSTF recommends against the use of ß-carotene or vitamin E supplements for the prevention of cardiovascular disease or cancer.
I The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the use of multivitamins for the prevention of cardiovascular disease or cancer.
I The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the use of single- or paired-nutrient supplements (except ß-carotene and vitamin E) for the prevention of cardiovascular disease or cancer.
Oral Cancer: Screening44 2013 I
Glaucoma: Screening45 2013 I
Bladder Cancer in Adults: Screening46 2011 I

________________________

42USPSTF, 2014a.

43USPSTF, 2014c.

44USPSTF, 2013b.

45USPSTF, 2013a.

46USPSTF, 2011.

Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×

REFERENCES

USPSTF (U.S. Preventive Services Task Force). 2011. Bladder cancer in adults: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/bladder-cancer-in-adults-screening (accessed August 17, 2021).

USPSTF. 2013a. Glaucoma: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/glaucoma-screening (accessed August 17, 2021).

USPSTF. 2013b. Oral cancer: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/oral-cancer-screening (accessed August 17, 2021).

USPSTF. 2014a. Dental caries in children from birth through age 5 years: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/dental-caries-in-children-from-birth-through-age-5-years-screening (accessed August 17, 2021).

USPSTF. 2014b. Suicide risk in adolescents, adults and older adults: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/suicide-risk-in-adolescents-adults-and-older-adults-screening (accessed August 17, 2021).

USPSTF. 2014c. Vitamin supplementation to prevent cancer and CVD: Preventive medication. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/vitamin-supplementation-to-prevent-cancer-and-cvd-counseling (accessed August 17, 2021).

USPSTF. 2015a. Iron deficiency anemia in pregnant women: Screening and supplementation. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/iron-deficiency-anemia-in-pregnant-women-screening-and-supplementation (accessed August 17, 2021).

USPSTF. 2015b. Iron deficiency anemia in young children: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/iron-deficiency-anemia-in-young-children-screening (accessed August 17, 2021).

USPSTF. 2015c. Speech and language delay and disorders in children age 5 and younger: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/speech-and-language-delay-and-disorders-in-children-age-5-and-younger-screening (accessed August 17, 2021).

USPSTF. 2015d. Thyroid dysfunction: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/thyroid-dysfunction-screening (accessed August 17, 2021).

USPSTF. 2016a. Aspirin use to prevent cardiovascular disease and colorectal cancer: Preventive medication. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/aspirin-to-prevent-cardiovascular-disease-and-cancer (accessed August 17, 2021).

USPSTF. 2016b. Autism spectrum disorder in young children: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/autism-spectrum-disorder-in-young-children-screening (accessed August 17, 2021).

USPSTF. 2016c. Breast cancer: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening (accessed August 17, 2021).

USPSTF. 2016d. Depression in children and adolescents: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/depression-in-children-and-adolescents-screening (accessed August 17, 2021).

USPSTF. 2016e. Impaired visual activity in older adults: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/impaired-visual-acuity-in-older-adults-screening (accessed August 17, 2021).

USPSTF. 2016f. Lipid disorders in children and adolescents: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lipid-disorders-in-children-screening (accessed August 17, 2021).

USPSTF. 2016g. Skin cancer: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/skin-cancer-screening (accessed August 17, 2021).

Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×

USPSTF. 2016h. Statin use for the primary prevention of cardiovascular disease in adults: Preventive medication. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication (accessed August 17, 2021).

USPSTF. 2017a. Celiac disease: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/celiac-disease-screening (accessed August 17, 2021).

USPSTF. 2017b. Gynecological conditions: Periodic screening with the pelvic examination. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/gynecological-conditions-screening-with-the-pelvic-examination (accessed August 17, 2021).

USPSTF. 2017c. Obstructive sleep apnea in adults: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obstructive-sleep-apnea-in-adults-screening (accessed August 17, 2021).

USPSTF. 2017d. Vision in children ages 6 months to 5 years: Screening. https://www.uspreventiveservices-taskforce.org/uspstf/recommendation/vision-in-children-ages-6-months-to-5-years-screening (accessed August 17, 2021).

USPSTF. 2018a. Adolescent idiopathic scoliosis: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/adolescent-idiopathic-scoliosis-screening (accessed August 17, 2021).

USPSTF. 2018b. Atrial fibrillation: Screening with electrocardiography. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/atrial-fibrillation-screening-with-electrocardiography (accessed August 17, 2021).

USPSTF. 2018c. Cardiovascular disease risk: Screening with electrocardiography. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cardiovascular-disease-risk-screening-with-electrocardiography (accessed August 17, 2021).

USPSTF. 2018d. Cardiovascular disease: Risk assessment with nontraditional risk factors. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cardiovascular-disease-screening-using-nontraditional-risk-assessment (accessed August 17, 2021).

USPSTF. 2018e. Child maltreatment: Interventions. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/child-maltreatment-primary-care-interventions (accessed August 17, 2021).

USPSTF. 2018f. Intimate partner violence, elder abuse, and abuse of vulnerable adults: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-screening (accessed August 17, 2021).

USPSTF. 2018g. Osteoporosis to prevent fractures: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening (accessed August 17, 2021).

USPSTF. 2018h. Peripheral artery disease and cardiovascular disease: Screening and risk assessment with the ankle-brachial index. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/peripheral-artery-disease-in-adults-screening-with-the-ankle-brachial-index (accessed August 17, 2021).

USPSTF. 2018i. Skin cancer prevention: Behavioral counseling. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/skin-cancer-counseling (accessed August 17, 2021).

USPSTF. 2018j. Unhealthy alcohol use in adolescents and adults: Screening and behavioral counseling interventions. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions (accessed August 17, 2021).

USPSTF. 2018k. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: Preventive medication. https://www.uspreventiveservices-taskforce.org/uspstf/recommendation/vitamin-d-calcium-or-combined-supplementation-for-the-primary-prevention-of-fractures-in-adults-preventive-medication (accessed August 17, 2021).

Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×

USPSTF. 2019a. Abdominal aortic aneurysm: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/abdominal-aortic-aneurysm-screening (accessed August 17, 2021).

USPSTF. 2019b. Elevated blood lead levels in children and pregnant women: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/elevated-blood-lead-levels-in-childhood-and-pregnancy-screening (accessed August 17, 2021).

USPSTF. 2020a. Bacterial vaginosis in pregnant persons to prevent preterm delivery: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/bacterial-vaginosis-in-pregnancy-to-prevent-preterm-delivery-screening (accessed August 17, 2021).

USPSTF. 2020b. Cognitive impairment in older adults: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cognitive-impairment-in-older-adults-screening (accessed August 17, 2021).

USPSTF. 2020c. High blood pressure in children and adolescents: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/blood-pressure-in-children-and-adolescents-hypertension-screening (accessed August 17, 2021).

USPSTF. 2020d. Illicit drug use in children, adolescents, and young adults: Primary care-based interventions. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-primary-care-interventions-for-children-and-adolescents (accessed August 17, 2021).

USPSTF. 2020e. Tobacco use in children and adolescents: Primary care interventions. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-and-nicotine-use-prevention-in-children-and-adolescents-primary-care-interventions (accessed August 17, 2021).

USPSTF. 2020f. Unhealthy drug use: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-screening (accessed August 17, 2021).

USPSTF. 2021a. Chlamydia and gonorrhea: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/chlamydia-and-gonorrhea-screening (accessed August 17, 2021).

USPSTF. 2021b. Gestational diabetes: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/gestational-diabetes-screening (accessed August 17, 2021).

USPSTF. 2021c. Hearing loss in older adults: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hearing-loss-in-older-adults-screening (accessed August 17, 2021).

USPSTF. 2021d. Tobacco smoking cessation in adults, including pregnant persons: Interventions. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions (accessed August 17, 2021).

USPSTF. 2021e. Vitamin D deficiency in adults: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/vitamin-d-deficiency-screening (accessed August 17, 2021).

Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Page133
Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Page134
Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Page135
Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Page136
Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Page137
Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Page138
Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Page139
Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Page140
Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Page141
Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Page142
Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Page143
Suggested Citation:"Appendix A: Topics with "I Statements" from the U.S. Preventive Services Task Force." National Academies of Sciences, Engineering, and Medicine. 2022. Closing Evidence Gaps in Clinical Prevention. Washington, DC: The National Academies Press. doi: 10.17226/26351.
×
Page144
Next: Appendix B: Research Methods »
Closing Evidence Gaps in Clinical Prevention Get This Book
×
Buy Paperback | $55.00 Buy Ebook | $44.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Closing Evidence Gaps in Clinical Prevention, a new consensus study report from the National Academies of Sciences, Engineering, and Medicine's Board on Population Health and Public Health Practice, evaluates evidence gaps in clinical prevention recommendations described by the United States Preventive Services Task Force and other clinical practice guideline developers and presents a taxonomy of these evidence gaps for future use. This report aims to improve the coordination of efforts to describe and communicate priority evidence gaps among funders and researchers. It also proposes new opportunities for collaboration among researchers, funders, and guideline developers to accelerate research that could close evidence gaps.

The authoring committee has also developed an interactive graphic that can be used as a workflow diagram for implementing the taxonomy. This workflow walks users through reviewing evidence, characterizing evidence gaps using relevant taxonomies, and developing a research agenda. Click here to view and engage with the interactive graphic.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!